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Dear Biochemical and Biophysical Research Communications Editor, 
 
Patients with severe chronic obstructive pulmonary disease (COPD) are known to have 
comorbidities. Therefore, treatment for COPD needs to focus on these comorbidities as well as the 
lungs. We previously reported a new IL-18 transgenic (Tg) COPD mice model. We analyzed 
comorbidities in IL-18 Tg mice for this paper. We found (1) Aging-related decrease of body weight 
in IL-18 Tg mice. (2) Decrease in the weight of the quadriceps femoris and gastrocnemius muscles 
in IL-18 Tg mice. (3) Decrease of bone mineral density in aged IL-18 Tg mice. (4) Impaired glucose 
tolerance in aged IL-18 Tg mice. We believe that our findings are one of the first reports the 
progression of comorbidity in IL-18 transgenic COPD mice model, may be of clinical benefit in the 
treatment of patients with severe COPD who have comorbidities and a poor clinical prognosis and 
the data will be of interest to the readers of Biochemical and Biophysical Research Communications. 
 
We look forward to hearing from you regarding its possible publication in Biochemical and 
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Patients with severe COPD are known to have comorbidities such as emaciation, cor 
pulmonale and right heart failure, muscle weakness, hyperlipemia, diabetes mellitus, 
osteoporosis, muscle atrophy, arterial sclerosis, hypertension, and depression. Therefore, 
treatment for COPD needs to focus on these comorbidities as well as the lungs. We 
previously reported a new mouse model of COPD utilizing the human surfactant protein 
C promoter SP-C to drive the expression of mature mouse IL-18 cDNA; constitutive 
IL-18 overproduction in the lungs of transgenic (Tg) mice induces severe 
emphysematous change, dilatation of the right ventricle, and mild pulmonary 
hypertension with aging. In the present study, we evaluated the progression of 
comorbidity in our COPD model. In female Tg mice, significant weight loss was 
observed at 16 weeks and beyond, when compared with control wild-type (WT) mice. 
This weight loss was suppressed in IL-13-deficient (knockout; KO) Tg mice. Muscle 
weight and bone mineral density were significantly decreased in aged Tg mice relative 
to control WT and IL-13 KO Tg mice. The aged Tg mice also showed impaired glucose 
tolerance. IL-18 and IL-13 may play important roles in the pathogenesis of comorbidity 
in COPD patients. 




Chronic obstructive pulmonary disease (COPD) is an important pulmonary 
inflammatory disease whose prevalence and associated mortality rates have been 
increasing [1,2]. COPD often coexists with other diseases (comorbidities) that may have 
a significant impact on prognosis. Comorbidities include cardiovascular disease (CVD) 
(such as ischemic heart disease, heart failure, hypertension, and pulmonary 
hypertension), osteoporosis, diabetes, infections, and lung cancer, and are common at 
any severity of COPD, so that differential diagnosis can often be difficult (see review 
[3]). It is thought that several common genetic or constitutional factors may predispose 
individuals with COPD to both pulmonary and systemic inflammation [4]. 
The proinflammatory cytokines IL-1, IL-18, IL-33, IL-36, IL-37, and IL-38 
belong to the IL-1 family [5]. IL-18 is well known to play an important role in Th1 
polarization, and can also act as a co-factor for Th2 cell development and IgE 
production [6,7,8,9]. IL-18 has been reported to take part in the differentiation of Th17 
cells by amplifying IL-17 production by polarized Th17 cells in synergy with IL-23 [10]. 
IL-18 plays important roles in the pathogenesis of inflammatory diseases such as atopic 
dermatitis [11], rheumatoid arthritis (RA), adult-onset Still‟s disease, Sjögren‟s 
syndrome, and inflammatory bowel diseases including Crohn‟s disease [see review [6]]. 
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IL-18 is also involved in the development of lung diseases including lung injury [12,13] 
and idiopathic pulmonary fibrosis (IPF) [14]. It has been shown that IL-18 and its 
receptor are involved in the pathogenesis of COPD [15,16,17]. Previously, we 
established a new animal model of COPD in which constitutive overproduction of 
mature IL-18 protein in the lungs of transgenic (Tg) mice resulted in severe emphysema 
accompanied by pulmonary inflammation. IL-13 gene deletion resulted in suppression 
of emphysema and inflammation in the IL-18 Tg mice [18]. In the present study, we 
evaluated comorbidity (in terms of body and muscle weight, bone mineral density, and 
glucose tolerance) and the roles of IL-13 in our COPD mouse model.  
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Materials and Methods 
Lung-specific IL-18-transgenic (Tg) mice 
We used female IL-18 Tg mice with a C57BL/6N (B6) background in which mature 
mouse IL-18 was overproduced in the lungs under the control of the human surfactant 
protein (SP) C promoter [18]. We established B6 background IL-13 deficient 
(knockout; KO) IL-18 Tg (IL-13KO/IL-18 Tg) mice by backcrossing IL-18 Tg mouse 
line A with B6 IL-13 KO mice, as reported previously [19]. Age-matched female B6 
wild-type (WT) mice, purchased from Charles River Japan (Yokohama, Japan), were 
used as controls. All procedures were approved by the Committee on the Ethics of 
Animal Experiments, Kurume University (Approval No. H22-079-084). Animal care 
was provided in accordance with the procedures outlined in the “Principle of laboratory 
animal care” (National Institutes of Health Publication No.86-23, revised 1985). 
 
Histological examinations 
For the histological analysis, mice were sacrificed with an intraperitoneal injection of 
sodium pentobarbital (2.5–5 mg per mouse). After gross examination, the extracted 
tissues were placed in 10% buffered formalin and further fixed for at least 24 hours. 
Sections (4 μm thick) were cut from paraffin-embedded tissues, placed on 
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poly-l-lysine-coated slides, and then incubated overnight at 55-60°C. Deparaffinized 
sections were stained with hematoxylin and eosin (HE), as reported previously 
[12,20,21]. 
 
Measurement of bone mineral density  
Mice aged 24 weeks were sacrificed, and the right thighbone of each was extirpated and 
cut into 20 slices 1 mm thick. Bone mineral density was analyzed by the DEXA 
(dual-energy X-ray absorptiometry) method using a DCS-600EX-ⅢR instrument 
(Aloka Corporation, Tokyo, Japan). The weight and surface area of each slice was 
measured, and the bone density (weight/surface area) calculated [22].  
 
Glucose tolerance test 
Glucose tolerance tests were performed as reported previously [23]. Briefly, a dose of 
glucose (1 g/kg) was administered by intraperitoneal (i.p.) injection, and the blood 
glucose level was measured at 0, 30, 60 and 120 minutes after the injection. 
 
Statistical analyses 
Results are expressed as means ± standard error of the mean (SEM). ANOVA was used 
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to compare differences between groups. The SAS 9.1.3 software package, Japanese 
edition (SAS Institute, Cary, NC, USA), was used for statistical analysis. P <0.05 was 




Aging-related body weight loss in IL-18 Tg mice  
We examined the body weight of female WT, IL-13 KO/IL-18 Tg, and IL-18 Tg mice 
every week from 7 to 24 weeks after birth (n=4 to 5 in each group). Representative 
results are shown in Figure 1. In WT, IL-13 KO/IL-18 Tg, and IL-18 Tg mice, body 
weight increased until 15 weeks of age. There was no significant difference in body 
weight among the groups until that time. From 16 to 24 weeks, body weight decreased 
significantly in IL-13 KO/IL-18 Tg and IL-18 Tg mice, when compared to WT mice. 
Interestingly, from 22 to 24 weeks, IL-18 Tg mice were significantly lighter than 
IL-13KO/IL-18 Tg mice. These results showed that weight loss was suppressed in 
IL-13KO/IL-18 Tg mice. 
 
Decrease of quadriceps femoris and gastrocnemius muscle weight in IL-18 Tg mice 
At 7 week of age, the quadriceps femoris muscle of WT mice was significantly heavier 
than that in IL-18 Tg and IL-13 KO/IL-18 Tg mice, although body weight did not differ 
significantly among the three groups (Fig. 1). There was no significant difference in 
muscle weight between IL-18 Tg and IL-13 KO/IL-18 Tg mice. At 16 weeks, the 
quadriceps femoris in WT mice was also significantly heavier than in IL-18 Tg and 
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IL-13KO/IL-18 Tg mice, and was significantly heavier in IL-13KO/IL-18 Tg mice than 
in IL-18 Tg mice. Interestingly, at 25 weeks, the quadriceps femoris was significantly 
heavier in WT and IL-13KO/ IL-18 Tg mice than in IL-18 Tg mice. There was no 
significant difference in quadriceps femoris weight between WT and IL-13KO/IL-18 Tg 
mice (Fig. 2). 
 At 7 weeks of age, the gastrocnemius muscle was significantly heavier in WT 
mice than in IL-18 Tg and IL-13KO/IL-18 Tg mice, but there was no significant 
difference in the weight of this muscle between IL-18 Tg and IL-13KO/IL-18 Tg mice. 
At 16 weeks and 25 weeks, the gastrocnemius was significantly heavier in WT and 
IL-13KO/IL-18 Tg mice than in IL-18 Tg mice, but showed no significant difference 
between WT and IL-13KO/IL-18 Tg mice (Fig. 2).  
 
Decrease of bone mineral density in aged IL-18 Tg mice 
Next, we examined bone mineral density in mice at 24 weeks of age. That in IL-18 Tg 
mice was significantly decreased in comparison with WT and IL-13KO/IL-18 Tg mice. 
However, there was no significant difference in bone mineral density between WT and 




Impaired glucose tolerance in aged IL-18 Tg mice 
We examined glucose tolerance in mice at 20 weeks of age. At 30 and 60 minutes after 
glucose administration, blood glucose levels showed no significant difference in IL-18 
Tg and WT mice. However, at 120 minutes after glucose administration, blood glucose 




COPD is characterized by an intense inflammatory process in the airways, parenchyma, 
and pulmonary vasculature. COPD is also associated with systemic inflammation [3,24]. 
For instance, the presence of systemic inflammation in COPD has been linked with a 
variety of complications including weight loss [25][26] [27], cachexia [28] [24], 
osteoporosis [29] [30] [31], cardiovascular disease [32] [33] [34], diabetes mellitus [35] 
[36], sleep disorder and depression [37,38]. It is has been reported that inflammatory 
cytokines including TNF-and IFN-may be involved in systemic inflammation in 
COPD [3]. However, the precise mechanisms of systemic inflammation in severe 
COPD are still uncertain. We showed previously that IL-18 was overexpressed in the 
lungs and serum of patients with very severe COPD [15]. Therefore, inflammatory 
cytokines including IL-18, TNF-and IFN- overexpressed in lung tissues may „„spill‟‟ 
over into the systemic circulation, promoting a generalized inflammatory reaction in 
COPD. 
We previously reported that constitutive overproduction of IL-18 in the lungs 
resulted in increased production of both Th1 and Th2 cytokines (including IFN-γ and 
IL-13), emphysematous changes, and severe pulmonary inflammation in the lungs of 
mice [18]. It has been reported that IL-18 produced by osteoblasts is a powerful 
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osteoclast-inhibitor [39]. Both IL-18 and IL-12 reduce the absorptive activity of 
osteoclasts through the production of IFN-γ [40]. Our present results showed that bone 
mineral density in IL-18 Tg mice was significantly decreased in comparison with WT 
and IL-13-deficient Tg mice, suggesting that IL-18 may inhibit the activities of 
osteoclasts partly through the production of IL-13 in IL-18 Tg mice. 
It has been reported that IL-18 mRNA was highly expressed in biopsy samples 
of skeletal muscle from COPD patients, relative to those from healthy controls [41]. 
There is some evidence that patients with COPD have increased skeletal muscle 
apoptosis [42]. Previous studies have shown that IL-18 causes apoptosis in various cell 
types including muscle cells and lymphocytes [43]. Here we showed that the weight of 
the quadriceps and gastrocnemius muscles was significantly decreased in aged IL-18 Tg 
mice, when compared with control WT and IL-13-deficient Tg mice, suggesting that 
overexpression of IL-18 may induce apoptosis in muscle cells via IL-13. However, we 
were unable to detect apoptotic muscle cells to any any significant degree in either the 
quadriceps of the gastrocnemius (data not shown). Further analysis will be needed to 
verify this issue. 
 It has been reported that 47% of COPD patients present 3 or more determinants 
of metabolic syndrome, including cardiovascular disease, diabetes mellitus, 
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hyperlipidemia, and hypertension [35]. Expression of IL-18 is increased in the retinas of 
diabetic OLETF rats, a model of type 2 diabetes mellitus, and chronic hyperglycemia 
accelerates the release of IL-18 and IFN-γ from inflammatory cells [44]. It is widely 
believed that IL-18 can exacerbate type 2 diabetes mellitus and cardiovascular disease 
[45]. Therefore, overexpression of IL-18 may induce hyperglycemia in patients with 
very severe COPD. 
Our present findings suggest that IL-18 and IL-13 may play important roles in 
the pathogenesis of comorbidity in COPD patients, and raise the possibility that 
blockade of IL-18 may be a feasible treatment for COPD. Caspase-1 inhibitors, 
antibodies against IL-18 and its receptor, IL-18 binding protein, or inhibitors of genes 
downstream of the IL-18 signal transduction pathway, such as those encoding MyD88, 
IL-1 receptor associated kinase, tumor necrosis factor receptor-associated factor 6, 
nuclear factor-kB, C-jun N-terminal kinase, and p38 mitogen-activated protein kinase, 
as well as IL-13 inhibitors, may be of clinical benefit in the treatment of patients with 







Figure 1. Aging-related decrease of body weight in IL-18-transgenic (Tg) mice.  
We examined the body weight of female WT, IL-13 KO/IL-18 Tg, and IL-18 Tg mice 
every week from 7 to 24 weeks from birth (n=4 to 5 in each group). 
*P<0.05: WT mice vs. IL-18 Tg mice. 
⋄ P<0.05: WT mice vs. IL-13KO/IL-18 Tg mice. 
†P<0.05: IL-18 Tg mice vs. IL-13KO/IL-18 Tg mice. 
 
Figure 2. Decrease in the weight of the quadriceps femoris and gastrocnemius 
muscles in IL-18 Tg mice. 
Mice (n=12 each group) were sacrificed at 7, 16, and 25 week after birth, and the 
weights of the quadriceps femoris and gastrocnemius muscles were measured. 
A) quadriceps femoris; B) gastrocnemius  
*P<0.05: WT mice vs. IL-18 Tg mice. 
⋄ P<0.05: WT mice vs. IL-13KO/IL-18 Tg mice. 




Figure 3. Decrease of bone mineral density in aged IL-18 Tg mice. 
Mice were sacrificed at 24 weeks of age (WT: n=7, IL-18 Tg: n=7, IL-13 KO/IL-18 Tg: 
n=8). Bone mineral density was measured as described in the Methods section. 
*P<0.05 
 
Figure 4. Impaired glucose tolerance in aged IL-18 Tg mice. 
Glucose tolerance tests were performed in mice at 20 weeks of age (WT: n=5, IL-18 Tg: 
n=5), as described in the Methods section. 
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